INC Research boosts infectious disease work buying Advanced Biologics.

RALEIGH, N.C.—INC Research, a therapeutically focused contract research organization (CRO), recently announced the strategic acquisition of Advanced Biologics to strengthen its infectious disease practice. Advanced Biologics is a full-service CRO specializing in full-service clinical development to the pharmaceutical and biotechnology industries worldwide.

"Advanced Biologics has built a world-class team of therapeutic experts that are focused on the needs of its clients," says James T. Ogle, CEO of INC Research. "We experience a tremendous amount of synergy with them on our approach to clinical trials—from how we kick-off a project, to how we develop a therapeutically-focused team, to how we ensure the accuracy and speed of the database lock. By joining forces, our clients will greatly benefit from our expanded infectious disease capabilities."

Advanced Biologics has full-service clinical development support for Phase I-IV clinical programs and has coordinated numerous IND, NDA, sNDA and ex-U.S. submissions. Beyond its infectious disease experience, the CRO also has handled studies for drugs being developed for cancer, neurological diseases, urologic conditions and women's health. Moreover, Advanced Biologics has comprehensive biostatistics experience, which extends into the pharmaceutical industry and regulatory agencies. In addition, INC Research reports it will fully leverage its Interactive Voice Response System technology, which provides patient randomization, stratification and data collection capabilities.

"We have already worked closely to ensure the integration of our teams, processes and technology is seamless for our clients. With our combined resources, we are well positioned to become an even stronger global force in the discovery and evaluation of new treatments for infectious diseases," says Michael Corrado, president and CEO of Advanced Biologics and now the CSO of INC Research.

Advanced Biologics, which is the largest employer in New Hope, Penn., will drop its own name, but will continue to function as a full-service drug development hub of operations, now serving as the seventh of INC Research's North American locations.